PPIDT00258
Drug Information
| Name | Metreleptin |
|---|---|
| Sequence | MVPIQKVQDDTKTLIKTIVTRINDISHTQSVSSKQKVTGLDFIPGLHPILTLSKMDQTLAVYQQILTSMPSRNVIQISNDLENLRDLLHVLAFSKSCHLPWASGLETLDSLGGVLEASGYSTEVVALSRLQGSLQDMLWQLDLSPGC |
| DrugBank_ID | DB09046 |
| Type | biotech |
| Indication | Metreleptin is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.[L41315,L49901] In Canada, it is additionally approved for use in patients ≥12 years old with confirmed familial partial lipodystrophy or acquired partial lipodystrophy (Barraquer-Simons syndrome) and persistent significant metabolic disease for whom standard treatments have failed to achieve adequate metabolic control.[L49901] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, powder, lyophilized, for solution | Subcutaneous |
11.3 mg/2.2mL
|
| Injection, powder, for solution | Parenteral; Subcutaneous |
11.3 MG
|
| Injection, powder, for solution | Parenteral; Subcutaneous |
3 MG
|
| Injection, powder, for solution | Parenteral; Subcutaneous |
5.8 MG
|
| Injection, powder, for solution | Subcutaneous |
11.3 mg
|
| Injection, powder, for solution | Subcutaneous |
3 mg
|
| Injection, powder, for solution | Subcutaneous |
5.8 mg
|
| Powder, for solution | Subcutaneous |
11.3 mg / vial
|
| Powder, for solution | Subcutaneous |
3 mg / vial
|
| Powder, for solution | Subcutaneous |
5.8 mg / vial
|